Sat, Dec 20, 2014, 10:22 AM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Novadaq Technologies Inc. Message Board

vonpezel 40 posts  |  Last Activity: Dec 11, 2014 10:19 PM Member since: May 3, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • vonpezel by vonpezel Dec 11, 2014 10:19 PM Flag

    nvdq kept its gains on unusually high 44K volume.
    The new interest seems to be continuing.
    Pezel

  • Reply to

    What's the deal?

    by shamelesspumpanddumper Dec 10, 2014 2:45 PM
    vonpezel vonpezel Dec 10, 2014 9:21 PM Flag

    I too would appreciate knowing more about the implications of this agreement with LifeNet Health. Can't seem to find a detailed listing of hospitals employing the company's products.
    Pezel

  • Reply to

    Natural cross selling opportunity

    by waitforgodot1 Dec 9, 2014 6:35 PM
    vonpezel vonpezel Dec 10, 2014 5:34 PM Flag

    I was scratching my head about the pop in the shares today...what caused it?
    We small fry on this board may never know but I suspect it's ALL of the above...all meaning the steady flow of announcements throughout the year---Lifecell, Taiwan, Japan, India, Australia, Indonesia,Pacific islands, Serena, patents, all the great news at the Investor Day conference which I attended in person, the new PInpoint with its improved images being introduced next month..etc. Today's news may have reflected the tipping point for the bulls...did I mention the shorts starting to capitulate?
    Comments?
    Pezel

  • Reply to

    Natural cross selling opportunity

    by waitforgodot1 Dec 9, 2014 6:35 PM
    vonpezel vonpezel Dec 10, 2014 8:11 AM Flag

    Novadaq Chosen Exclusive Distributor of DermACELL Tissue Products
    BY Midnight Trader
    — 6:59 AM ET 12/10/2014

    06:59 AM EST, 12/10/2014 (MT Newswires) -- Novadaq (NVDQ ) was chosen as the exclusive worldwide distributor of DermACELL tissue products for wound and breast reconstruction surgery. The deal has an initial 10-year term but can be renewed for successive five-year periods, depending on certain conditions.

    DermACELL, created by transplant solutions provider LifeNet Health, is a allograft bio-implant used in breast reconstruction surgeries, as well as in the treatment of diabetic foot ulcers and chronic non-healing wounds.
    Pezel

  • vonpezel vonpezel Dec 9, 2014 3:56 PM Flag

    thanks for this post.
    Pezel

  • Reply to

    Piper Jaffray 26th Annual Healthcare Conference

    by buzzybob Dec 3, 2014 6:41 AM
    vonpezel vonpezel Dec 8, 2014 12:21 PM Flag

    "I am hoping that he indicates continued growth in the 40% range and increased gross margins".
    Arun has stated that he expects gross margins to push into the high 60s, possibly bumping 70 into next year. Remember on the last cc, he revealed the 3 metrics that analysts should use to rate the company: gross margins, revenues and procedures
    Pezel

  • Reply to

    Piper Jaffray 26th Annual Healthcare Conference

    by buzzybob Dec 3, 2014 6:41 AM
    vonpezel vonpezel Dec 4, 2014 9:53 PM Flag

    Today Novadaq may be a "risky" stock ( no profit or dividend).. Next year, if and when profits make their long awaited appearance, the stock may move out of the "risky" category., and thus be largely unaffected when "risk off:"sentiment rules any given trading day.

  • Reply to

    Piper Jaffray 26th Annual Healthcare Conference

    by buzzybob Dec 3, 2014 6:41 AM
    vonpezel vonpezel Dec 4, 2014 6:16 PM Flag

    Possibly impatient day traders/short sellers didn't like hearing about the year long phased in repatriation of LIfecell into Novadaq's business. The short interest, already at a record high probably went higher still. Question for the board: what catalyst will most likely trigger a catchup buying frenzy?

  • Reply to

    Institutional ownership

    by e11ndofwar Nov 24, 2014 11:09 AM
    vonpezel vonpezel Nov 24, 2014 7:46 PM Flag

    Looking good!
    Pezel

  • Reply to

    Recent decline

    by e11ndofwar Nov 20, 2014 7:59 AM
    vonpezel vonpezel Nov 20, 2014 8:21 AM Flag

    good thinking
    Pezel

  • Reply to

    Investor Day Eyewitness Report

    by vonpezel Nov 17, 2014 8:47 PM
    vonpezel vonpezel Nov 18, 2014 1:42 PM Flag

    no, Rick tossed it off as a passing remark.
    but my ears perked up!
    This is good news for both nvdq and isrg.
    Pezel

  • Reply to

    Investor Day Eyewitness Report

    by vonpezel Nov 17, 2014 8:47 PM
    vonpezel vonpezel Nov 18, 2014 8:12 AM Flag

    Yes, the drop in the shares was a jolt. I mentioned this to an analyst at the conference.. He kind of shrugged his shoulders, and said there was no real dramatic trigger to kick up the shares, everything was already known. My own opinion is that the market suffers from ADD
    (attention deficit disorder). When the market decides to pay attention, it will make up for lost time in a hurry and dramatically jolt the shares up to where they belong....wishful thinking?
    Pezel

  • Reply to

    Investor Day Eyewitness Report

    by vonpezel Nov 17, 2014 8:47 PM
    vonpezel vonpezel Nov 18, 2014 7:58 AM Flag

    stay tuned for more (later today)
    Pezel

  • Reply to

    Investor Day Eyewitness Report

    by vonpezel Nov 17, 2014 8:47 PM
    vonpezel vonpezel Nov 18, 2014 7:56 AM Flag

    Back to Roger Decks presentation~
    He repeated that the new Pinpoint will be out in Jan of 2015.
    Its much sharper images (which I saw with my own eyes in the lobby before the conference began)
    will "end the conversation" of image quality".
    Moving on to Luna, Roger reiterated a key point that Arun has made in the past~
    when diabetics actually see the diagnostic images of their own condition, they will lead the charge
    to comply with their doctors' orders. Furthermore these images are recurring with changes in the patient's condition,
    an incentive for diabetics to actually see and measure their progress on the road to recovery.
    He mentioned 600K as a "sweet spot"for Luna.
    He completed his presentation with references to radiopharmaceuticals and the acquisition of Aimago.
    Next up was a 10 minute film entitled "Novadaq's Commitment to Medical Education".
    On the subject of future growth for the company~
    Arun will be addressing the "big issue" of CMS reimbursements.
    Other vehicles of future growth~
    The company will integrate Lifecell in " 6 to 9 months".
    The "halo effect" will kick in during the 2nd half of 2015.
    The Japanese market is as large as one third of the U.S. Market.
    China and India are in the early stages of building 1000 hospitals per year.
    In Europe the awareness (of SPY) is there, and the population is aging.
    Socialized medicine in Europe means that all can jump on board together,
    once top down decision makers give the word.
    (When I asked Arun about a presence in South America, he agreed that it's "in the works")
    Rick Mangat said that the company will use the existing SPY systems already placed
    in 400 hospitals to grow more procedures.
    He also spoke about a future hand held modular device which will gradually be introduced.

  • Reply to

    Investor Day Eyewitness Report

    by vonpezel Nov 17, 2014 8:47 PM
    vonpezel vonpezel Nov 18, 2014 7:51 AM Flag

    One other idea from Sales VP Tom Tamberrino~
    He threw in "off balance" 3rd party financing options for prospective purchasers of nvdq equipment.
    This guy seems like the real deal.
    Doug Carroll, (around the Globe in 8 minutes) quantified Novadaq's opportunity as follows~
    2.1 Billion to 4.2 Billion, doubling the U.S. opportunity of 1-2 Billion.
    Here's another gem: OUS, SLN (Sentinel Lymph Node) procedures are already approved!
    (but still waiting on FDA approval here in the states).
    He put up a screen listing at least 2 dozen countries that are on his radar for sales.
    Japan and China were at the top.
    Doug made the point that sales procedures in ROW would follow the same time tested procedures
    already being employed here at home, starting with influencing "key opinion leaders" or KOL.
    Roger Deck (department of Innovations) started off with a history of Novadaq's innovations
    (including bypass grafts, perfusion of the colon, SLN mapping, NIR and white light on the same camera).
    He mentioned a "ton of information" and patents to go with it,
    all to keep Novadaq's "first mover advantage in the market place".
    As of Sept 30, 2014, the company has 49 patent families.
    At this point, allow me to fast forward to a conversation I had with an analyst upon leaving the conference.
    This person thinks it's "50-50" that Novadaq's patents (IP) may not stand up in court in a challenge from Stryker.
    He thinks fluorescent imaging and differentiating images with black and white is not necessarily home grown with Novadaq.
    This disarmed me, and make me wonder if Novadaq's patents are really foolproof as a bar to entry.
    Further, this analyst thought that it would be cheaper for Stryker to fight Novadaq in court, than acquire the company in a buyout....
    Back to Roger Decks presentation~
    He repeated that the new Pinpoint will be out in Jan of 2015.
    Its much sharper images (which I saw with my own eyes in the lobby before the conference began)
    will "end the conversation" of image qualit

  • Reply to

    Investor Day Eyewitness Report

    by vonpezel Nov 17, 2014 8:47 PM
    vonpezel vonpezel Nov 17, 2014 9:13 PM Flag

    Thanks for the kind words....don't shoot the messenger!

  • Reply to

    Investor Day Eyewitness Report

    by vonpezel Nov 17, 2014 8:47 PM
    vonpezel vonpezel Nov 17, 2014 8:55 PM Flag

    ** Here's a little gem: Rick met with CMS 2 weeks ago---they won't be paying hospitals for readmissions!.
    He said this is "exciting"---and it is!
    He then went down the list: esophagus, gyn, liver, urology, cardio, vascular, wound care, sentinel lymph notes (SLN).
    In Q1 of 2015, the company will begin a new clinical study of wound care/therapy in 20/25 centers.
    Pillar 3 will be a "groundbreaking" trial with 400/800 patients.
    Sloan Kettering wants SPY as standard of care, I believe 10 sites in new SLN study.
    Whew! Eyes are closing (I got up at 4:45 AM for you guys)...tune in for part 2 tomorrow.
    Your faithful SPY,
    Pezel

  • Reply to

    Investor Day Eyewitness Report

    by vonpezel Nov 17, 2014 8:47 PM
    vonpezel vonpezel Nov 17, 2014 8:54 PM Flag

    Today represented the coming out party for the management team, comprised of:
    Rick Mangat, founder and now general manager, Tom Tamberrino, VP for sales, Doug Carroll (globalization) and Roger Deck (Innovations).
    I was particularly impressed with Tom, who actually remembered me from last year's conference!
    (He's one of the Life Cell people who's now with Novadaq).
    Tom spoke abut the "synergies" of SPY, Pinpoint and Luna and dividing up the sales agenda among devices, software, services and disposables.
    He also will be zeroing in on "corporate and national accounts".
    Sales "reps" are out---sales "pros" are in, presently at 60 strong on the way to 80; 10 clinical people on the way to 20, 2 national accounts people on the way 3, and 10 in management.
    His sales force will be concentrating on clinical results, economic value, closing sales, the growing pipeline of applications, and increasing utilization by stressing peer to peer contacts in various specialties of medicine. I got the impression he is very determined and very focused.
    His 4 part "plan of attack" is to focus on the Veterans Administration, Critical Access hospitals, Community hospitals and "academics".
    I definitely think he's the right man for the job.
    Rick Mangat spoke about the importance of clinical trials for the ultimate success of the company.
    (I kind of think he's the brains of the entire operation).
    Rick started off by telling us that clinical studies of SPY now total 120, with 3 or 4 being added each quarter!
    He stressed the value of clinical studies to drive adaption.
    Breast recon now has software that quantifies perfusion, and currently with 18% penetration, "no more data is needed" to "take a good part of the market" and make it SOC.
    As for colorectal, Rick reviewed the results of Pillar 2 (1.4% leak rate, vs. previously 12.6% without SPY)
    Also 8% of procedures were changed by using SPY with subsequent ZERO leaks!

  • As promised, here's my takeaway from today's Investor Day program in the grand ballroom of the Sofitel Hotel in NYC.
    There were 96 name tags prepared; almost all actually attended.
    Usual suspects included Rick Wise from Stifel, Matt Miksic (Piper Jaffray) and Margaret Kaczor ( William Blair).
    Before the program got underway, I spoke with some members of management.
    They seemed friendly enough, and eager to volunteer information.
    Standing in front of the prominently displayed new PInpoint, John Fengler (research) told me
    that its rollout will take place in Jan of '15. He thought that surgeons would really appreciate
    the improved clarity of its images, especially around the far reaches of the images.
    John also explained to me that with Pinpoint, only fluorescent lighting is needed...
    as opposed to Firefly, where the surgeon has to switch back and forth between white and fluorescent lights.
    So it seems that Arun has reserved the best of SPY for Pinpoint and not for Firefly.
    Also had a few words with Lori Swalm (Regulatory and government Affairs) and Roger Deck, who had substituted
    for Arun on a recent webcast with analysts, and who is now responsible for Innovations.
    I thanked Arun for all his efforts in creating the positive flow of good news about the company,
    He smiled and said that he couldn't clone himself, and that credit should go to his management team.
    And that indeed proved to be one of the two main theme of this investor conference (the other being the growing applications for PInpoint, Luna and SPY Elite).
    Beginning the presentations, Arun spoke about the "continuum" of Spy, Pinpoint and Luna.
    With SPY already in 400 hospitals, he spoke about the "halo effect" of adding Luna and Pinpoint for the same customers.
    The new PInpoint will be "application specific", but did not clarify further.
    He also reminded us that Firefly is standard on the new DaVinci Xi model.
    Today represented the coming out party for the management team, comprised of:
    Rick Ma

    Sentiment: Strong Buy

  • Reply to

    Institutional Exposure

    by e11ndofwar Nov 16, 2014 7:33 AM
    vonpezel vonpezel Nov 16, 2014 5:39 PM Flag

    good research, thank you.
    Pezel

NVDQ
16.29-0.10(-0.61%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.